4//SEC Filing
Miller Steve 4
Accession 0001161697-24-000505
CIK 0001369568other
Filed
Dec 10, 7:00 PM ET
Accepted
Dec 11, 5:00 PM ET
Size
13.2 KB
Accession
0001161697-24-000505
Insider Transaction Report
Form 4
Miller Steve
VP Development & Management
Transactions
- Exercise/Conversion
Common stock, par value $0.001 per share
2024-12-10$4.01/sh+50,000$200,500→ 736,996 total - Exercise/Conversion
Common stock, par value $0.001 per share
2024-12-09+11,872→ 686,996 total - Sale
Common stock, par value $0.001 per share
2024-12-10$21.93/sh−50,000$1,096,350→ 686,996 total - Exercise/Conversion
Restricted Stock Units
2024-12-09−11,872→ 1,837,176 total→ Common Stock (11,872 underlying) - Exercise/Conversion
Options to purchase common stock
2024-12-10−50,000→ 1,787,176 totalExercise: $4.01Exp: 2025-01-02→ Common Stock (50,000 underlying)
Footnotes (6)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
- [F2]Shares were sold on the open market for personal reasons and not as a result of any disagreement with the Company.
- [F3]Represents a weighted average price for the shares sold. Shares were sold in a range between $21.73 and $22.09 per share.
- [F4]Derivative securities vest in equal tranches, 1/3rd on December 8, 2024, 1/3rd on December 8, 2025 and 1/3rd on December 8, 2026.
- [F5]Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on December 9, 2024.
- [F6]Options vested in three annual tranches beginning on January 2, 2019.
Documents
Issuer
CATALYST PHARMACEUTICALS, INC.
CIK 0001369568
Entity typeother
Related Parties
1- filerCIK 0001402535
Filing Metadata
- Form type
- 4
- Filed
- Dec 10, 7:00 PM ET
- Accepted
- Dec 11, 5:00 PM ET
- Size
- 13.2 KB